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Abstract
Background: In order to accurately distinguish gaps of varying length in drug treatment for chronic conditions
from discontinuation without resuming therapy, short-term observation does not suffice. Thus, the use of
inhalation corticosteroids (ICS) in the long-term, during a ten-year period is investigated. To describe medication
use as a continuum, taking into account the timeliness and consistency of refilling, a Markov model is proposed.
Methods: Patients, that filled at least one prescription in 1993, were selected from the PHARMO medical record
linkage system (RLS) containing >95% prescription dispensings per patient originating from community pharmacy
records of 6 medium-sized cities in the Netherlands.
The probabilities of continuous use, the refilling of at least one ICS prescription in each year of follow-up, and
medication free periods were assessed by Markov analysis. Stratified analysis according to new use was
performed.
Results: The transition probabilities of the refilling of at least one ICS prescription in the subsequent year of
follow-up, were assessed for each year of follow-up and for the total study period.
The change of transition probabilities in time was evaluated, e.g. the probability of continuing ICS use of starters
in the first two years (51%) of follow-up increased to more than 70% in the following years. The probabilities of
different patterns of medication use were assessed: continuous use (7.7%), cumulative medication gaps (1–8 years
69.1%) and discontinuing (23.2%) during ten-year follow-up for new users. New users had lower probability of
continuous use (7.7%) and more variability in ICS refill patterns than previous users (56%).
Conclusion: In addition to well-established methods in epidemiology to ascertain compliance and persistence, a
Markov model could be useful to further specify the variety of possible patterns of medication use within the
continuum of adherence. This Markov model describes variation in behaviour and patterns of ICS use and could
also be useful to investigate continuous use of other drugs applied in chronic diseases.
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Background
Chronic diseases have become more prevalent in the last
decades and will be in the decades to come [1,2]. Patients
suffering from these conditions need to adapt their behav-
iour, including taking medication, for a longer period of
time, in order to decrease the risk of morbidity and mor-
tality in the long-term. The effect of treatment on disease
outcome depends for the greater part on whether sus-
tained behaviour change has been achieved.
Medication use in chronic conditions may not always be
characterized by one or several prolonged periods of drug
taking in a steady dose. In some conditions like asthma,
self-management allows patients, depending on their
severity of disease, to adjust the timing and dosing of
inhaled corticosteroids (ICS) [3-5]. Whether appropriate
or not, it is very likely that the use of medication in other
chronic diseases might vary similarly. Adherence rates are
generally higher among patients with acute conditions
compared to those suffering chronic disease, whether not
symptomatic or with recurrent episodes of more frequent
and more severe symptoms [6].
Adherence to pulmonary medication has shown great var-
iability [6-9]. Although data on adherence are often
reported as dichotomous variables (adherence vs. non-
adherence), adherence can vary along a continuum [9-11]
and only a fraction of studies have characterised medica-
tion use as such [12,13]. Discontinuation of medication
has been shown to increase morbidity and mortality in
asthma [14-16] and has been associated with several other
diseases such as cardiovascular disorders [17,18].
Survival probabilities of continuous use are usually
assessed, assuming that at the end of observation, patients
were either continuous users of medication during the
preceding period of follow-up or not [19]. This is inherent
to single event analysis; once a patient does not fill a pre-
scription during a certain interval, the patient is excluded
from further analysis.
As the measures developed for estimating compliance
from pharmacy data fail to capture the timeliness and
consistency of refilling, measures to estimate persistence
with medication refilling have been described. Measure-
ment of medication persistency attempts to capture the
amount of time that an individual remains on chronic
drug therapy. Persistent individuals refill their medica-
tions frequently and regularly. In contrast, non-persistent
individuals have a range of refilling practices or have dis-
continued refilling their medications completely. Instead
of discontinuing treatment, which implies cessation of
drug therapy with no future resumption of treatment, a
patient may only have a temporary gap in treatment. Due
to the relatively short duration of follow-up in most stud-
ies such temporary gaps in treatment will be considered as
medication discontinuation [13]. In order to distinguish
between these drug-taking behaviours with certainty, a
long time horizon is necessary.
In asthma medication use had only been investigated dur-
ing a maximum of two years of follow-up. Adherence
(30% – 60%) and persistence rates with ICS are generally
low [6,9]. The variety in results of studies on continuation
of ICS use is probably due to differences in design, meth-
ods and population. Different methods for assessing con-
tinuation, comprising self-report, canister weight,
physicians' estimates and pharmacy records, can explain
the different results [6,9].
ICS are a type of drug that poses some methodological dif-
ficulties when analysing (non)adherence and establishing
the appropriateness of medication use. Guidelines recom-
mend to adjust the daily dose of ICS according to the
severity of symptoms e.g. because of seasonal influences
[3]. Classic survival analysis with discontinuation as a
dichotomous measure has some limitations when aiming
to describe the patterns of drug utilisation over a pro-
longed period of time.
We therefore aimed at characterising the different patterns
of use that emerge from medication-taking behaviour in
chronic disease, with a Markov chain model. With this
model the probability of various patterns can be assessed
assuming patient's prescription (re) filling during a fixed
period. The model is explained by applying it to the (re)
filling of ICS prescriptions during a maximum duration of
ten years in a cohort that filled at least one ICS prescrip-
tion in 1993 stratified according to new use.
Methods
Setting
We used data from the ongoing PHARMO record-linkage
system (PHARMO RLS), which contains drug-dispensing
pharmacy records from community pharmacies of 6
medium-sized cities in the Netherlands [20], covering 2%
of the total Dutch population and more than 95% of all
prescriptions dispensed to a particular patient [21]. Since
the majority of all patients in the Netherlands are regis-
tered only with one community pharmacy, independently
of prescriber, pharmacy records are virtually complete
with regard to prescription drugs. Drugs are coded accord-
ing to the Anatomical Therapeutic Chemical (ATC) classi-
fication. As PHARMO RLS collects data anonymously,
according to current Dutch law no ethical approval for
this study is required. Pharmacists that do provide dis-
pensing data to PHARMO RLS do inform patients in gen-
eral about he fact that anonymous data from their
pharmacy can be used for research purposes.BMC Health Services Research 2007, 7:106 http://www.biomedcentral.com/1472-6963/7/106
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Study sample
We selected all patients that filled at least one prescription
for an ICS in 1993. Of these patients the complete history
of filled prescriptions from 1-1-1991 until 31-12-2002 or
the end of patient observation was available. The end of
follow-up is determined by PHARMO RLS either as the
last date any prescription was filled by a patient at one of
the pharmacies or a record of death within one of the hos-
pitals in the linkage system.
Statistical analysis
The probability of continuous use and the probability of
cumulative gaps during follow-up were assessed by use of
a Markov model (see additional file 1) for the total popu-
lation adjusting for censoring. The two-sided confidence
intervals for probabilities were computed applying the
bootstrap method (see additional file 1) [22].




In theory, after the filling of each prescription a patient
has to decide whether or not to continue his drug therapy.
This means that before filling the next prescription there
is a certain probability that a patient will continue drug
therapy or discontinue. In time this can result in one or
several changes in refill behaviour. The patients' actions,
refilling a prescription or not in several fixed periods
throughout the study period, can be analysed by a Markov
chain model. With the Markov model we describe it is
possible to assess the probability of various patterns,
instead of just continuous use and/or discontinuation.
The patients' refill behaviour is characterized by the filling
of at least one ICS prescription within fixed periods (cal-
endar years) during follow-up.
In this particular Markov chain model the states are
defined as the years of follow-up. A patient is considered
to be in a particular state if he/she has filled at least one
Examples of patterns of medication use during follow-up Figure 1
Examples of patterns of medication use during follow-up. In these examples patients are observed during maximum follow-up. 
1a A patient with continuous use throughout the study period. 1b A patient with periods of ICS prescription refill in subse-
quent years of follow-up and two separate years without a refill prescription; cumulative medication gap of two years. 1c A 
patient with periods of ICS prescription refill in subsequent years of follow-up and two consecutive years without a refill pre-
scription; cumulative medication gap of two years. 1d A patient, that did not refill an ICS prescription during follow-up while 
still under observation.BMC Health Services Research 2007, 7:106 http://www.biomedcentral.com/1472-6963/7/106
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ICS prescription in the associated year. If a patient first
filled a prescription in a particular yeari, and subsequently
in another yearj, and not in the years between yeari and
yearj, the patient made a transition from state " yeari" to
state " yearj". The state "> 2002" was defined and patients
with transitions into it are patients that are not censored
before the end of the study (31-12-2002) and of which no
assessment of medication use can be performed due to the
end of (study) follow-up. The transitions after the end of
follow-up are unknown. Transitions from each state are
the filling of a prescription in the next calendar year, in
one of the other following years or in none of the years
while under observation. For each state several transitions
from and into another state are possible. As the filling of
at least one prescription for an ICS is an inclusion crite-
rion for the cohort all patients are present in the state
year93. The first state, 1993, has no transition into it. The
number of possible transitions for each state depends on
the number of remaining years of follow-up after yeari.
The later the year under consideration, the less the
number of possible transitions becomes. For example, the
first year of follow-up, 1993, has the most number of
achievable transitions to another state; 10 and the last
year of follow-up, 2002, has the least; 1. Clearly the state
">2002" has no transitions to other states.
As stated before transition probabilities can be assessed
for the transition from statei into statej, to be more precise
yeari into yearj. To do so, a period of at least two consecu-
tive years is necessary. From the state "2002" patients can
only have transitions into ">2002" due to the end of fol-
low-up. A first-order Markov chain model like the one we
describe (see appendix) implies that the presence in a par-
ticular state only depends on the presence in the directly
preceding state but is independent of all former states.
This means that the probability of having filled at least
one ICS prescription in 1996 and subsequently filling at
least one prescription for an ICS in one of the following
years, for instance 1997, are conditional to having filled at
least one prescription in a preceding year. To have a tran-
sition from 1996 to another state, e.g. to refill a prescrip-
tion in one of the years after 1996, a patient should have
filled at least one prescription in one of the years before
1996. The possible transitions into the state, 1996, are 1)
year93→year96  (the previous prescription(s) filled in
1993), 2) year94→year96  (the previous prescription(s)
filled in 1994), 3) year95→year96, (the previous prescrip-
tion(s) filled in 1995). E.g. in possibility 2) filling at least
one prescription in 1997 given 1996; 1994; 1993, the
transition from year96→year97 is conditional only to the
transition from year94→year96 regardless of the transition
into year94.
The transition matrix gives an overview of the probabili-
ties for all possible transitions throughout the study
period. The sum of all possible transition probabilities
from a certain state is 1. As the states in this model are
defined as subsequent time periods, the transition matrix
is a visual description of possible behaviour and change in
time. It is therefore possible to detect a change in time of
a certain transition probability, e.g. for the filling of the
next prescription in the immediately following year.
The occurrence of continuing ICS use can be affected by
several factors, possibly leading to confounding. In order
to adjust for potential confounding, a stratified analysis
according to these factors can be performed. An important
confounder is the history of patients at the start of the
study. Previous users are "survivors" of the early period of
pharmacotherapy and are likely to have a higher probabil-
ity of continuous use [23]. Therefore new and previous
users were defined based on the use of ICS in 1991 and/
or 1992.
Continuous use
The transition probabilities for the filling of at least one
ICS prescription for all different years of follow-up, can be
combined (see appendix) in order to assess the probabil-
ity of a particular "route" throughout the total period of
follow-up, such as continuous use of ICS (Figure 1). In the
content of this study continuous use was defined as the
filling of at least one prescription for an ICS in each year
of follow-up (calendar year) (Figure 1a). A sensitivity
analysis was performed with more strict definitions of at
least two and at least three prescriptions filled per year.
Table 1: Baseline characteristics of the study population in intitial year of study (Undetermined previous use due to insufficient 
medication history prior to 1993 for 386 (4.2%) patients)
At least one ICS prescription filled in 1993 New users Previous users (≥ 1 prescription in 1991 or 1992)
(% or range) (% or range)
All patients 3,367 (36.5) 5,481 (59.4)
Male (%) 1,629 (48.4) 2,813 (51,3)
Mean age (yrs) 43.9 (0–94) 50.7 (2–99)
Mean follow-up (yrs) 7.7 (0.04–10.3) 7.7 (0.02–10.3)
Mean number of ICS prescriptions filled in 1993 2.2 (1–28) 3.6 (1–25)BMC Health Services Research 2007, 7:106 http://www.biomedcentral.com/1472-6963/7/106
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Medication gaps
Some of the conceivable patterns of patients' variable pre-
scription refill behaviour are shown in Figure 1. The dis-
tribution of patterns with different numbers of
cumulative gaps for the follow-up period can be obtained
by use of the transition matrix.
Medication gaps were defined as "calendar years without
any prescription for an ICS". The occurrence of a gap of
one year in the period [1993; 1995] would result in the
filling of the next prescription for an ICS in 1995 after
1993, which corresponds to the transition probability
P93→95 (see appendix). The probabilities of cumulative
gaps were assessed during the total duration of follow-up
(see appendix), for example the probability of a gap of
one year T9 [1993, >2002] - T8 [1993, >2002], cumulative
gap of five years, and so on. Gaps could be in consecutive
years or spread over several years. A patient with a cumu-
lative gap duration of two years could have filled prescrip-
tions for ICS in 1993 and for instance subsequently in
each year during follow-up, except for 1995 and 2000
(Figure 1b). Another patient could have the same cumula-
tive gap duration with a prescription in each year during
follow-up, except for 1995 and 1996 (Figure 1c).
Results
In 1993, a total of 9,234 patients filled at least one pre-
scription for an ICS. Of all patients receiving ICS in 1993,
5481 (59.4%) were characterised as previous users of ICS
as they filled at least one prescription in 1991 or 1992.
Based on this classification, 3367 (36.5%) patients were
characterised as new users of ICS. The history preceding
1993 was not available for 386 patients (4.1%), as these
were not observed during the two previous years. From
this population, 57.0% was followed for ten years, the
maximum duration of follow-up. The mean follow-up
was 7.7 years (Table 1).
Continuous use
Probabilities of continuous use and medication free peri-
ods were assessed for the total population and stratified
according to new use. Previous users had a higher proba-
bility of continuous use, 39.8% (95% C.I. 22.1–26.0%)
than new users, 7.8% (95% C.I. 6.8–8.7%). The probabil-
ities obtained for new users are presented in table 3 and
Figures 2, 3, 4.
The probabilities of continuous use hardly varied with
more strict definitions of continuous use. The probabili-
ties of continuous use for new users with a definition of at
least two or at least three prescriptions per year were
respectively 10.2% (95% C.I. 8.6–11.8) and 10.2% (95%
C.I. 8.6–11.8) (data not shown).
For each year the transition probabilities, assessed by
Markov analysis, are presented in Table 1. The transition
probabilities for any of the years of follow-up, are printed
in the rows. To clarify the outcome, transition probabili-
ties for only 1993 are shown in Figure 2. The transition
probabilities for the refilling of a prescription in any of the
subsequent years of follow-up for every state can be writ-
ten out in the same way. As stated earlier the probabilities
of transitions for a particular event from different states
can be combined (see appendix) in order to assess the
probability of a particular "route" during follow-up.
In 1994, year 1 and 2 of follow-up have elapsed and the
maximum duration of use that can be obtained is two
years, 37.2% of the patients filled a prescription in both,
1993 and 1994. By combining (see appendix) the transi-
tion probability of the filling of a prescription in 1994
(p93→94) with the probability of filling the next prescrip-
tion in 1995 (p94→95) the prevalence of patients that are
Transition probabilities from one particular state, 1993, to all  other possible states for new users are shown Figure 2
Transition probabilities from one particular state, 1993, to all 
other possible states for new users are shown. The transi-
tion probability of filling at least one ICS prescription in 1994, 
given filling at least one prescription in 1993, P93→94, is 51%. 
One of the possible transitions is "1993" → "after end of fol-
low-up".BMC Health Services Research 2007, 7:106 http://www.biomedcentral.com/1472-6963/7/106
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continuous users in 1994 (0.51*0.73*100% = 37.2%) is
obtained. Based on the first order Markov model, which
assesses conditional transition probabilities, a patient that
was a continuous user in 1996, has been a continuous
user in every previous year (p93→94 * p94→95 *p95→96). In
1996 (0.51*0.73*0.75*100% =) 27.9% filled a prescrip-
tion in every preceding year.
Figure 3 illustrates that patients do not refill a prescription
for an ICS in each year of follow-up and in time this
results in variable patterns.
3a For new users, the probabilities of continuous use, gaps and discontinuation in the period that has elapsed until a particular  year of follow-up Figure 3
3a For new users, the probabilities of continuous use, gaps and discontinuation in the period that has elapsed until a particular 
year of follow-up. 3b For new users, for each year of follow-up the proportion of patients with irregular ICS use (medication 
free periods) and continued ICS use in the period of follow-up that has elapsed until then are shown.BMC Health Services Research 2007, 7:106 http://www.biomedcentral.com/1472-6963/7/106
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As explained earlier, the population was stratified accord-
ing to previous and new use of ICS. The probability after
ten years of follow-up was 39.7% (95% C.I. 38.0–41.3)
for previous users and was substantially lower for new
users, 7.8% (95% C.I. 6.8–8.7). It is possible to investigate
whether this lower probability of continuous use in 1993
is constant and sustained for each state throughout the
study. In the first year of follow-up 85.1% (95% C.I. 84.1–
86.0) of the previous users continued ICS use as opposed
to 51.0% (95% C.I. 49.4–52.9) of the new users. After the
first three years the probability increased to 79% and sta-
bilises (Table 2, printed in bold).
Medication gaps
Markov analysis was used to ascertain the probability of
medication free periods of several lengths. Of the patients
observed in 1993, the year of start for new users, 51.0%
(95% C.I. 49.4–52.9) filled at least one prescription in the
following year (Table 3 top row, Figure 2). In this first
year, 1993, new users had a probability of 11% (95% C.I.
9.7–11.8) for a gap of exactly one year, the filling of the
next prescription for an ICS in 1995 (Table 3 top row, Fig-
ure 2).
In addition to a lower probability of continuous use, new
users tend to have medication free periods of three years
or longer (69.1%), more frequently than previous users
(56%) (Figure 4). Besides the filling of a prescription in
each year (continuous use), not in all years of follow-up
(gaps), not refilling a prescription (discontinuation) was
also considered one of the possible patterns of medication
use. The probability of discontinuation of ICS refilling
after 1993 throughout the study is higher in new users
(23.2%) than in previous users (4.3%). These findings
illustrate that new users have more variability in patterns
of ICS use during a period of ten years.
Discussion
The Markov chain model that was designed enables to
describe the variable patterns that emerge from refilling
ICS prescriptions during a period of maximum possible
follow-up of ten years among patients that filled at least
one ICS prescription in 1993 in the PHARMO RLS. New
users of ICS in 1993 have a lower probability of continu-
ous use and more variability in patterns of ICS use than
previous users. This can be completely attributed to the
finding that the probability of continuing treatment into
the next year increased for new users from 51% in the first
two years to more than 70% in the following years. New
use and long-term persistence have, to our knowledge, not
been well investigated among ICS users, but similar differ-
ences between new and previous users have also been
shown in other drug treatment regimens [23].
Chronic diseases require long-term adjustments in
patients' behaviour, such as medication taking behaviour.
Potential consequences of medication non-adherence
include disease progression in chronic illness, and the
subsequent need for more aggressive treatments, which
further increases the risk of (drug-induced) illness [14-
16,18]. In chronic conditions, especially when not symp-
Table 2: Matrix of transition probabilities. The states in this model are defined as the years of follow-up
T = 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 >2002 Total
1993 0 0.51 0.11 0.04 0.03 0.03 0.02 0.01 0.01 0.01 0.23 1
1994 0 0 0.73 0.08 0.05 0.02 0.02 0.01 0.004 0.01 0.09 1
1995 0 0 0 0.75 0.10 0.03 0.01 0.01 0.01 0.01 0.08 1
1 9 9 60000 0.79 0.08 0.02 0.02 0.01 0.01 0.07 1
1 9 9 700000 0.79 0.08 0.03 0.01 0.01 0.07 1
1 9 9 8000000 0.78 0.09 0.03 0.02 0.09 1
1 9 9 90000000 0.80 0.07 0.03 0.10 1
2 0 0 000000000 0.81 0.08 0.10 1
2 0 0 1000000000 0.87 0.13 1
2 0 0 2000000000011
> 2 0 0 2 000000000011
The probability of gaps, medication free periods of several  lengths, in the total population and stratified for new and  previous use Figure 4
The probability of gaps, medication free periods of several 
lengths, in the total population and stratified for new and 
previous use.BMC Health Services Research 2007, 7:106 http://www.biomedcentral.com/1472-6963/7/106
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tomatic, motivation might change over time adding sub-
stantially to the variability in adherence to preventer
medication, leading to worsening of the condition. In our
study the probability of continuing ICS use of starters in
the first two years was lowest and increased to approxi-
mately the same probability as for previous users in the
following years. Although "survival" of a group of patients
with higher persistence was expected [23,24] this is not
observed in all studies on persistence in new users [25].
Clinical implications
It is important to realise that patients might discontinue
for several reasons. Patients using ICS, however most fre-
quently do not discontinue entirely but use their medica-
tion intermittently or during annual periods often based
on seasonal variety of symptoms. When initiating ther-
apy, patient and physician should therefore agree on the
intended duration of use and subsequently evaluate the
experience of symptoms and the use of ICS. By reviewing
dispensing data pharmacists could assist physicians in
monitoring adherence. Patients' previous experiences
with a specific drug treatment should be discussed as these
experiences might influence future behaviour.
Research implications
Often medication use, not only in asthma, is studied only
during a short period of time as a dichotomous outcome
[7-9,11-13,24,25] and not often in relation to clinical out-
come [26,27]. The necessary level of adherence for treat-
ment effectiveness depends on the drug and the disease,
rendering meaningless any arbitrary distinction between
"adherent" and "non-adherent". Therefore, there is a need
for describing medication use as a continuum and the var-
ying patterns in time. The analysis of drug dispensing
records often results in aggregated population characteris-
tics, which do not clarify individual changes in medica-
tion. Consequently deviant behaviour is not easily
detected. As patient profiles and drug-use patterns over
time are important determinants of treatment outcomes,
a method that characterizes individual behaviour over a
longer period of time is needed.
In the frequently applied two state model a patient "dis-
appears" from the analysis after the (first) event. In the
Markov model described a patient stays in the analysis
after the first event, which gives more insight into differ-
ent behaviour patterns of long-term medication use.
Moreover, a Markov model can be intuitively graphically
understood which is a clear advantage for interpretational
purposes.
Detailed information on dosing schedules and differences
in type and number of prescription drugs used can further
characterise drug-use patterns. This detailed information
can also help to understand patient behaviour. Further-
more, drug related characteristics such as initiation, refill-
ing, switching and discontinuation could be analysed
[28]. In this Markov model the transition states were
defined as a certain number of prescriptions filled per year
to describe refill behaviour in patients using asthma pre-
venter therapy. Additionally, states can be defined by
applying previously described methods for assessing drug
exposure, such as single or multiple-interval measures of
medication gaps [12,13]. Thus combining accepted meth-
ods in epidemiology and a relatively new type of model-
ling, which previously has been applied to great extent in
economics and has not been used often in clinical epide-
miology.
Conclusion
In addition to well-established methods in epidemiology
to ascertain compliance and persistence, a Markov model
could be useful to further specify the variety of possible
patterns of medication use within the continuum of
adherence. This Markov model describes variation in
behaviour and patterns of ICS use and could also be also
be used to investigate patterns of use of other drugs
applied in chronic diseases.
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